研究業績

論文・出版

2022年


Switch maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial


Shigehira Saji, Naruto Taira, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Tohru Ohtake, Tatsuya Toyama, Yuichiro Kikawa, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba,, Takanori Ishida,Rikiya Nakamura, Yutaka Yamamoto, Uhi Toh, Hiroji Iwata, Norikazu Masuda, Satoshi Morita, Shinji Ohno, Masakazu Toi


Lancet Oncol . 2022 May;23(5):636-649


doi: 10.1016/S1470-2045(22)00196-6.

Immune microenvironment, homologous recombination deficiency and therapeutic response to neoadjuvant chemotherapy in triple negative breast cancer : Japan Breast Cancer Research Group (JBCRG)22 TR


Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Tomohiro Chiba, Takayuki Kadoya, Hiroko Bando, Takashi Yamanaka, Shoichiro Ohtani, Shigenori Nagai, Takahiro Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravindranath M. Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi


BMC Medicine 2022 Apr 25;20(1):136.


doi: 10.1186/s12916-022-02332-1.

Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative breast cancer: An ad-hoc analysis of the JBCRG-C06 Safari study


Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno


Japanese Journal of Clinical Oncology, 2022


https://doi.org/10.21203/rs.3.rs-190374/v1

任意団体JBCRG 研究業績